Company · CIK 0001534120 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Avalo Therapeutics, Inc. · AVTX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 SForm 4 → | Sep 18, 4:10 pm EDT | Christopher Ryan SullivanChief Financial Officer | 12,394 | $16.33 | $202,437 | 39,900 | −23.7% | 10b5-1 |
| Sep 16, 2026 MForm 4 → | Sep 18, 4:10 pm EDT | Christopher Ryan SullivanChief Financial Officer | 12,394 | $9.88 | $122,453 | 52,294 | — | 10b5-1 |
| Sep 10, 2026 SForm 4 → | Sep 11, 4:10 pm EDT | Christopher Ryan SullivanChief Financial Officer | 10,185 | $17.62 | $179,457 | 39,900 | −20.3% | 10b5-1 |
| Sep 10, 2026 MForm 4 → | Sep 11, 4:10 pm EDT | Christopher Ryan SullivanChief Financial Officer | 10,185 | $8.04 | $81,887 | 50,085 | — | 10b5-1 |
| Aug 28, 2026 SForm 4 → | Sep 1, 4:38 pm EDT | Mittie DoyleChief Medical Officer | 679 | $20.00 | $13,580 | 51,776 | −1.29% | 10b5-1 |
| Aug 28, 2026 MForm 4 → | Sep 1, 4:38 pm EDT | Mittie DoyleChief Medical Officer | 679 | $8.04 | $5,459 | 52,455 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 MForm 4 → | Sep 18, 4:10 pm EDT | Christopher Ryan SullivanChief Financial Officer | 12,394 | — | — | 83,848 | — | 10b5-1 |
| Sep 10, 2026 MForm 4 → | Sep 11, 4:10 pm EDT | Christopher Ryan SullivanChief Financial Officer | 10,185 | — | — | 105,815 | — | 10b5-1 |
| Aug 28, 2026 MForm 4 → | Sep 1, 4:38 pm EDT | Mittie DoyleChief Medical Officer | 679 | — | — | 113,734 | — | 10b5-1 |